Aspirin and warfarin for thromboembolic disease after total joint arthroplasty

• Published in: Clinical orthopaedics and related research no. 324; p. 251
• Main Authors: Lotke, P A, Palevsky, H, Keenan, A M, Meranze, S, Steinberg, M E, Ecker, M L, Kelley, M A
• Format: Journal Article
• Language: English
• Published: United States 01.03.1996
• Subjects: Aged; Anticoagulants - therapeutic use; Aspirin - therapeutic use; Female; Humans; Joint Prosthesis; Male; Platelet Aggregation Inhibitors - therapeutic use; Postoperative Complications - prevention & control; Prospective Studies; Pulmonary Embolism - prevention & control; Thromboembolism - prevention & control; Treatment Outcome; Warfarin - therapeutic use
• ISSN: 0009-921X
• DOI: 10.1097/00003086-199603000-00031

This study compares the benefits of aspirin and warfarin prophylactic agents for patients with thromboembolic disease after total joint arthroplasty. It is a prospective randomized study of 388 patients having total hip or total knee surgery. All consecutive patients having total hip or total knee surgery were entered into this study and evaluated with preoperative and postoperative ventilation perfusion scans and a postoperative venogram. The aspirin and warfarin treatment groups were compared by size and location of venographically revealed clots and changes in ventilation perfusion scans. The results showed that there was no difference in the size or location of deep venous thrombosis in the aspirin or warfarin treatment groups. The venogram was negative in 44.5% of patients; 28.8% had small ++calf clots, 16% had large calf clots, 3.9% had popliteal clots, and 6.7% had femoral clots. Patients with total knee replacement had a 2.6 times greater incidence of calf deep venous thrombosis than patients with total hip replacement. There was no difference between the aspirin and warfarin groups in the incidence of changes in ventilation perfusion scans (18.9%). There was no difference between the 2 groups in bleeding complications. The results suggest that aspirin and warfarin are equivalent in prophylaxis against thromboembolic disease, as determined by prevention of venographic changes or changes in ventilation perfusion scans.